International Journal of Trichology

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 14  |  Issue : 3  |  Page : 91--96

Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study


Rattapon Thuangtong, Saroj Suvansuthi, Pitchaya Maneeprasopchoke, Thanisorn Sukakul, Rattiya Techakajornkeart, Pichanee Chaweekulrat, Supisara Wongdama, Daranporn Triwongwaranat 
 Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Correspondence Address:
Daranporn Triwongwaranat
Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700
Thailand

Background: The combination of diphenylcyclopropenone (DCP) and anthralin may demonstrate synergistic effects in the treatment of chronic extensive alopecia areata (AA). Objective: The objective of the study was to compare the efficacy of the combination therapy of topical DCP and topical 0.5% anthralin versus topical DCP alone for the treatment of chronic extensive AA. Materials and Methods: Ten patients were included in the study. Of these, 1, 2, and 7 patients were diagnosed with alopecia totalis, severe AA (>50% hair loss), and alopecia universalis, respectively. For each patient, one side of the scalp was treated with a DCP solution and 0.5% anthralin for 6 months, while the other side was treated with DCP and a cream base for the same duration. The clinical responses were assessed at baseline and then monthly until the end of the 6-month study period using the Severity of Alopecia Tool score. The side effects were evaluated at each follow-up visit. Results: The difference in the efficacies of the combination treatment and DCP alone was not statistically significant (P = 0.59). Regarding the side effects, DCP plus 0.5% anthralin caused significantly more excessive dermatitis than DCP alone (7 patients vs. 2 patients; P = 0.02). Eight patients reported temporary hyperpigmentation at the combination-treatment site, whereas no hyperpigmentation was reported at the DCP-alone site of any patient (P < 0.001). Conclusions: The combination of DCP and 0.5% anthralin was not superior to DCP alone for the treatment of chronic extensive AA. An increase in side effects – excessive dermatitis and hyperpigmentation – was observed in the combination-treatment group.


How to cite this article:
Thuangtong R, Suvansuthi S, Maneeprasopchoke P, Sukakul T, Techakajornkeart R, Chaweekulrat P, Wongdama S, Triwongwaranat D. Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study.Int J Trichol 2022;14:91-96


How to cite this URL:
Thuangtong R, Suvansuthi S, Maneeprasopchoke P, Sukakul T, Techakajornkeart R, Chaweekulrat P, Wongdama S, Triwongwaranat D. Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study. Int J Trichol [serial online] 2022 [cited 2022 Jun 26 ];14:91-96
Available from: https://www.ijtrichology.com/article.asp?issn=0974-7753;year=2022;volume=14;issue=3;spage=91;epage=96;aulast=Thuangtong;type=0